Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data
International Journal of Urology · 2024
DOI: 10.1111/iju.15437 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Koichi Uemura und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yokohama City University Hospital, Kanagawa, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Objective
In December 2021, enfortumab vedotin (EV), an antibody‐drug conjugate directed against nectin‐4, was approved in Japan as a new treatment after platinum‐containing chemotherapy and PD‐1/PD‐L1 inhibitors. This study evaluated, using real‐world data, the efficacy and safety of EV therapy in patients with metastatic urothelial carcinoma (mUC). Materials and methods Fifty‐five patients with mUC who discontinued pembrolizumab therapy due to disease progression between June 2018 and April 2023 at Yokohama City University Hospital were evaluated retrospectively. Of the 55 patients, 25 received EV therapy (EV group) and 30 did not (non‐EV group). All patients who underwent EV therapy were diagnosed with disease progression after the approval of EV in Japan.
Results
The median (range) follow‐up period after pembrolizumab discontinuation was 6.3 (0.7–31.1) months. There were eight (32.0%) deaths due to cancer in the EV group and 27 (90.0%) in the non‐EV group. The overall survival (OS) after pembrolizumab discontinuation was not reached in the EV group versus 2.6 months in the non‐EV group ( p < 0.001). A multivariate analysis revealed that EV therapy (EV vs. non‐EV group; hazard ratio 0.26; 95% confidence interval 0.16–0.41; p < 0.001) was an independent prognostic factor for OS.
Conclusion
EV prolonged OS in mUC following pembrolizumab therapy in real‐world data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Yokohama City University Hospital, Kanagawa, Japan.
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan.
ORCID-Profile: Koichi Uemura, Tomoyuki Tatenuma, Takashi Kawahara, Kentaro Muraoka, Kazuhide Makiyama
Zitieren
APA
Uemura, K., Ito, H., Jikuya, R., Kondo, T., Tatenuma, T., Kawahara, T., Ito, Y., Komeya, M., Muraoka, K., Hasumi, H., Uemura, H., & Makiyama, K. (2024). Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data. International Journal of Urology. https://doi.org/10.1111/iju.15437
Vancouver
Uemura K, Ito H, Jikuya R, Kondo T, Tatenuma T, Kawahara T, et al. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data. International Journal of Urology. 2024. doi:10.1111/iju.15437
BibTeX
@article{Uemura2024,
author = {Uemura, Koichi and Ito, Hiroki and Jikuya, Ryosuke and Kondo, Takuya and Tatenuma, Tomoyuki and Kawahara, Takashi and Ito, Yusuke and Komeya, Mitsuru and Muraoka, Kentaro and Hasumi, Hisashi and Uemura, Hiroji and Makiyama, Kazuhide},
title = {Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15437}
}
EUVIMED